Bandaram Pharma Packtech Limited has announced its unaudited financial results for the quarter and nine months ended 31.12.2025. The Board of Directors approved the standalone and consolidated financial results along with limited review reports during their meeting held on 13.02.2026 at 4:30 p.m. at the company's registered office in Bangalore, concluding at 7:10 p.m.

Regulatory Compliance and Board Meeting

The company submitted its outcome under Regulation 30 read with 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to BSE Limited. The results were prepared in accordance with Ind AS-34 "Interim Financial Reporting" and reviewed by statutory auditors M M Reddy & Co., Chartered Accountants, who provided limited review reports for both standalone and consolidated results.

Financial Performance Overview

The company's financial performance for Q3FY26 showed contrasting results between standalone and consolidated operations. The results demonstrate the impact of the company's subsidiary operations on overall performance.

Nine Months Performance Analysis

For the nine months ended 31.12.2025, the company's performance showed different trends across standalone and consolidated operations.

Earnings Per Share Details

The company reported earnings per share figures for both basic and diluted calculations across continuing operations.

Subsidiary Operations

The consolidated results include the performance of two subsidiary companies. VSR Paper & Packaging Limited, in which Bandaram Pharma Packtech holds a 55% stake, and Craftsmart Products Private Limited, which is 100% owned by the company. According to the auditor's review report, VSR Paper and Packaging Limited reported total revenues of Rs. 1,398.76 lakhs and net profit of Rs. 73.76 lakhs for Q3FY26, while Craftsmart Products Private Limited recorded revenues of Rs. 25.38 lakhs and net profit of Rs. 0.38 lakhs.

Corporate Actions and Compliance

The company has acquired shareholders of Craftsmart Products Private Limited on a swap basis in the ratio of 5:4, meaning for every 5 equity shares of Rs. 10 each held in Craftsmart Products Private Limited, 4 equity shares of Rs. 10 each of Bandaram Pharma Packtech Limited will be issued. The financial results have been prepared in accordance with Ind AS-34 "Interim Financial Reporting" and have been reviewed by statutory auditors M M Reddy & Co., Chartered Accountants, who provided limited review reports for both standalone and consolidated results.

Bandaram pharma packtech Limited has announced key changes to its Board of Directors following a meeting held on 30.01.2026. The pharmaceutical packaging company made strategic appointments and accepted a resignation that will reshape its board composition.

Board Meeting Outcomes

The Board of Directors convened on Friday, 30.01.2026 at 05:10 p.m. at the company's registered office located at Oxford Towers, Old Airport Road, Kodihalli, Bangalore. The meeting, which concluded at 5:40 p.m., addressed critical governance matters under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

New Director Appointment Details

Mr. Eswar Reddy Putturu has been appointed as an Additional Director in the Non-Executive Independent category, subject to shareholder approval. His appointment is for a period of 5 years effective from 30.01.2026.

Professional Background

Mr. Putturu brings significant expertise to the board with his MBA in Finance & Marketing. His professional profile highlights:

• Expertise in marketing banking products and financial analysis
• Excellence in customer acquisition and relationship management
• Experience in delivering tailored financial solutions
• Focus on aligning business growth with customer needs

Director Resignation

Mrs. Priyanka Agarwal submitted her resignation from the position of Non-Executive Independent Director, citing personal reasons. Her resignation became effective from the close of business hours on 30.01.2026.

Other Directorships

At the time of her resignation, Mrs. Agarwal held directorship positions in:

• Midland Polymers Limited
• Cura Technologies Limited

In her resignation letter, Mrs. Agarwal confirmed that there were no material reasons for her resignation beyond the personal reasons mentioned. She expressed gratitude to her board colleagues and wished the company success in its endeavors.

Regulatory Compliance

The company has fulfilled all disclosure requirements under SEBI regulations, providing comprehensive details in Annexure-A as mandated by Part A of Schedule III and Regulation 30. The announcement was signed by Deepak Reddy B, Chairman and Managing Director (DIN: 07074102), ensuring proper corporate governance protocols were followed throughout the process.